Home > News & Events > News
Three Experts from China-Japan Friendship Hospital, including Drs.Li Ping, Zhang Hongchun, Jin Ming were honored “Qihuang Scholars”
Source: Posted Date:01-03-2019

On December 25, 2018, the State Administration of Traditional Chinese Medicine issued a notice,announcing the name list of Qihuang Scholars of “100 million” talent project of Chinese medicine inheritance and innovation through the recommendation of departments, online primary election, conference selection, on-site defense, and candidate selection. Professor Li Ping, Professor Zhang Hongchun and Professor Jin Ming (sorted in the stroke order of surnames) of China-Japan Friendship were elected as “Qihuang Scholars”.
To promote the construction of the leading talents of Traditional Chinese medicine, the State Administration of Traditional Chinese Medicine organized and implemented National Traditional Chinese Medicine Leadership Support Program, and formulated the “Millions of Talents Project of  Traditional Chinese Medicine Heritage and Innovation” (Qihuang Project) – the leading talents of Traditional Chinese Medicine Supporting Program which aims to promote the development of traditional Chinese medicine through the selection of hundreds of scholars and fully utilize the leading role of leading talents to promote the development of Traditional Chinese medicine. According to the requirements, the scholars should cooperate with experts in relevant fields, carry out innovative, exploratory and applied research in accordance with the development needs and key issues of Traditional Chinese medicine, strengthen team building, and actively promote the resolution of clinical or scientific problems in the development of Chinese medicine. A landmark achievement has been made with greater influence inside and outside the industry. The research capabilities of Chinese medicine have been significantly improved, guiding the development of Traditional Chinese Medicine. China-Japan Friendship Hospital will give full play to the leading role of the leading talents of " Qihuang Scholars", further improving the academic and clinical capacities, continuously upgrading the scientific and technological innovation and social services, and contributing to the futuer development of Traditional Chinese Medicine.
Li Ping, female, has doctorate degree of medicine and is a researcher, chief physician, doctoral tutor. She has been engaged in the research of Traditional Chinese Medicine for 36 years with clinical efficacy evaluation and related mechanism research of Traditional Chinese Medicine for treating chronic kidney disease as her main research direction.
In the 1980s, Li Ping studied under Professor Zhen Zhensheng, a famous expert Traditional Chinese Medicine nephrology, and obtained a master and doctor degree in TCM internal medicine at Institute of Traditional Chinese Medicine. He was awarded the Shichuan Medicine Scholarship twice and obtained a Ph.D. in Western Medicine from Niigata University, Japan. For more than 30 years, she has devoted herself to the study of Traditional Chinese medicine nephrology, adhering to the combination of Chinese and Western medicine, and using modern medical methods to study and analyze the scientific connotation of traditional Chinese medicine.
She has engaged in more than 20 national and provincial research projects, including national 973, key international cooperation projects, and major research projects of National Natural Science Foundation. She has published more than 200 academic papers about Traditional Chinese Medicine in journals and academic conferences at home and abroad, including more than 60 papers in SCI, 12 academic books, and 5 academic books. She has made positive contributions to the international exchange of Traditional Chinese medicine. In 2003, she was awarded as an advanced individual who returned to China after studying abroad. In 2007, she was awarded the outstanding female science and technology expert of State Central Organ and the first outstanding female Chinese medicine practitioner. In 2007-2008, she was selected in the young and middle-aged experts with outstanding contributions from the Ministry of Health and received special allowances from the State Council; in 2011, she won the Outstanding Contribution Award for the implementation of the National Science and Technology Plan of the 11th Five-Year Plan. In 2018, she won the honorary title of the national three-eighth red flag bearer.
The research team led by Dr. Li was selected as the key research center for clinical evaluation of chronic kidney disease in State Administration of Traditional Chinese Medicine in 2008. In 2009, it was selected as the C-level laboratory of kidney pharmacology of the State Administration of Traditional Chinese Medicine. In 2010, it was selected as the key subject of integrated Chinese and Western medicine in the State Administration of Traditional Chinese Medicine. In 2014, it was again selected as the key laboratory of Beijing immuno-inflammatory diseases.
As the project leader, she has won more than 10 scientific and technological progress awards at all levels in the past ten years, and in 2016, the clinical and basic research on the treatment of diabetic nephropathy with dominant proteinuria with her as the core was awarded the second prize for scientific and technological progress.
Zhang Hongchun, male, has a doctor degree of medicine, and is chief physician, as well as doctoral tutor. He also serves as the member of the 13th National Committee of the Chinese People's Political Consultative Conference and the member of the 13th National Committee of the CPPCC Agriculture and Rural Committee. Having engaged in traditional Chinese medicine research for 33 years, he specializes in the the clinical and clinical basis of Chinese medicine pulmonary diseases.
Under the guidance of Professor Guo Enxiang, master in the field of Traditional Chinese medicine, Professor Zhang Hongchun took the lead, proposing that "wind and stagnation, airway urgency" is the main pathogenesis of asthma attack, and established the effective treatment of "disintegration of wind and phlegm" in the treatment of acute asthma attack. He carried out related researches on the meaning of "wind snarl", "wind cough" and syndromes, and won the 2009 China Science and Technology Society First Prize and the Beijing Science and Technology Award Third Prize. His main research results were adopted by the "Consensus Opinions of Cough Chinese Medicine Experts (2011 Edition)" and "Common Opinions of Traditional Chinese Medicine Diagnosis and Treatment of Bronchial Asthma (2012 Edition)", and were included in the relevant chapters of the textbook "Chinese Medicine Internal Medicine". Actively participating in and promoting the standardization of the diagnosis and treatment of traditional Chinese medicine pulmonary diseases, under the leadership of famous traditional Chinese medicine doctors such as Professor Wang Yongyan and Professor Yan Enxiang, he participated in the Clinical Clinical Medicine Internal Medicine, Today's Traditional Chinese Medicine (Series), and the Clinical Research of New Drugs in Traditional Chinese Medicine. "Guidelines" and other monographs and norms writing (drafting) work, working on regulating TCM internal medicine and Chinese medicine emergency disease diagnosis and treatment technology; As the chairman of the Chinese Society of Traditional Chinese Medicine Pulmonary Diseases, he presided over and participated in the "Chinese medicine common disease diagnosis and treatment guide (2008 edition), "Cough Chinese Medicine diagnosis and treatment expert consensus", "bronchial asthma Chinese medicine diagnosis and treatment expert consensus", "Influenza Chinese medicine new drug guiding principle", and acquired pneumonia in community and other common lung diseases TCM syndrome diagnostic criteria and diagnosis and treatment, making outstanding contributions to the standardization of TCM diagnosis and treatment of Chinese medicine. Paying attention to the clinical efficacy and mechanism of traditional Chinese medicine in the stable phase of pulmonary diseases, relying on the National Science and Technology Support Program "Major Difficult Diseases Chinese Medicine Prevention and Control Research" major project, the National Natural Science Foundation Project carried out the immune mechanism of Guben Zhike Chinese medicine on respiratory mucosa. In the study, the second phase clinical approval of “Tiaofeifeishen Capsule” was obtained, and the clinical guidelines for the stable phase of COPD were developed and applied nationwide. He actively carry out research on the prevention and treatment of influenza syndrome in traditional Chinese medicine, as well as research on prescription drugs, and drafted the guiding principles for clinical research on the treatment of influenza by Chinese medicine.
He has presided over 12 provincial-level and above TCM clinical research or research projects and won 7 provincial and ministerial-level scientific and technological awards. As the first author or the author of the communication, he has published more than 50 papers and 13 monographs on various core journals; he was honored with outstanding national science and technology workers and advanced individuals in the central health care work.
Jin Ming, female, has a master’s degree of medicine, and serves as chief physician, as well as doctoral tutor. She has engaged in traditional Chinese medicine research for 36 years, with the diagnosis and treatment of Chinese medicine ophthalmology diseases as her main research subject.
As the academic leader of "Beijing Traditional Chinese Medicine Ophthalmology Clinic", she always regard the treatment and diagnosis of traditional Chinese and Western medicine for eye diseases as the unique character, and dares to challenge difficult fundus diseases and optic neuropathy, making solid scientific research in evidence-based, clinical and basic. She has undertaken many key special disease projects of the “Eleventh and Twelfth Five-Year Plan” of the Central Management Bureau, and has been awarded the title of “National Senior Chinese Medicine Doctors and Teachers” (5th and 6th batches). And she has been working as an expert in central health consultation. She has obtained more than 20 national, provincial and ministerial-level projects, and conducted a series of in-depth studies on fundus diseases including degenerative, vascular, immune and hereditary fundus lesions, and won provincial and ministerial-level achievement awards for 7 times. She has published more than 150 papers, edited 5 books and co-edited 9 items; She has trained more than 50 master doctors, and more than 10 disciples, and made more than 100 academic speeches in the country. She has made great academic achievement and industry influence. She has served as the chairman of the Chinese Traditional Medicine Association Eye Department, and now serves as the chairman of the China Traditional Medicine Association Eye Care Committee and the member of the National Central Management Bureau Standardization Technical Committee, leading the industry in the development and revision of guidelines. A lot of work has been done on areas such as consensus and standards by her. In 2016, due to outstanding performance, she was awarded the first China National Contribution Award for "Giving Life and Glory Medicine".
She is good at the diagnosis and treatment of age-related macular degeneration. The Huangma No. 1 has been patented by the state and has been transformed into results, forming the academic idea of "benefiting Qi, regulating blood circulation and removing blood stasis". The combination of Macular I and anti-neovascular injection has the effects of improving efficacy, improving vision and reducing the number of injections. She is good at the treatment of difficult diabetic macular edema, and innovatively puts forward that "yang deficiency and blood stasis" is the core pathogenesis, forming the academic thinking of "Guyang Xiaoyu". The yellow spot II has been patented, and the innovative combination of the yellow spot II combined with minimally invasive photocoagulation solves the bottleneck problem that the macular edema is difficult to subside. In 2018, she won the second prize of China's integrated Chinese and Western medicine technology.
She is also the first to establish a unique neuro-ophthalmology joint outpatient clinic in Beijing, interdisciplinary integration, collaboration between Chinese and Western medicine, and remarkable results in the diagnosis and treatment of visual impairment caused by difficult optic atrophy: hormones, immunosuppressive agents, plasma exchange, application. She plays a prominent role in reducing recurrence, reducing side effects; traditional acupuncture treatment to improve vision and recovery, which were welcomed by patients. She also adheres to his main academic thought of "Spillar yang, Shugan Yu, Zhuangshen Shui" is the main academic idea.
She emphasizes the inheritance and innovation of ocular surface external treatment, develops the experience of Fang Jieyi I treatment of acute and chronic conjunctivitis, conjunctival II prescription for all kinds of dry eye syndrome, conjunctival III prescription for allergic conjunctivitis which have been made in the hospital The preparation, using the ultrasonic atomizer as a carrier for ocular fumigation treatment, which has benefited tens of thousands of people. She has obtained 3 patents.
In order to build a big data platform for traditional Chinese medicine treatment of fundus blood syndrome, she combined cross-disciplinary simulation technology to establish a simulation model of fundus vascular disease, trying to quantify the blood and blood stasis of Chinese medicine, and using the visualization platform to predict cardiovascular and cerebrovascular diseases.